102 related articles for article (PubMed ID: 25834916)
21. [Factors of resistance of ovarian cancer to combined chemotherapy with the use of platinum derivatives].
Bliumenberg AG; Gorbacheva LB; Gorbunova VA; Kozachenko VP; Lankin VZ
Biull Eksp Biol Med; 1996 Dec; 122(12):651-4. PubMed ID: 9280465
[No Abstract] [Full Text] [Related]
22. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.
Mayr D; Pannekamp U; Baretton GB; Gropp M; Meier W; Flens MJ; Scheper R; Diebold J
Pathol Res Pract; 2000; 196(7):469-75. PubMed ID: 10926324
[TBL] [Abstract][Full Text] [Related]
23. The influence of theobromine on angiogenic activity and proangiogenic cytokines production of human ovarian cancer cells.
Barcz E; Sommer E; Sokolnicka I; Gawrychowski K; Roszkowska-Purska K; Janik P; Skopinska-Rózewska E
Oncol Rep; 1998; 5(2):517-20. PubMed ID: 9468592
[TBL] [Abstract][Full Text] [Related]
24. Rhabdomyosarcoma arising in a mature cystic teratoma with contralateral serous carcinoma: case report and review of the literature.
Kefeli M; Kandemir B; Akpolat I; Yildirim A; Kokcu A
Int J Gynecol Pathol; 2009 Jul; 28(4):372-5. PubMed ID: 19483625
[TBL] [Abstract][Full Text] [Related]
25. Ovarian low-grade serous carcinoma involving the cervix mimicking a cervical primary.
Malpica A; Deavers MT
Int J Gynecol Pathol; 2011 Nov; 30(6):613-9. PubMed ID: 21979600
[TBL] [Abstract][Full Text] [Related]
26. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
27. [Current status and future developments in chemotherapy of advanced epithelial ovarian cancers (author's transl)].
Szepesi T
Wien Klin Wochenschr; 1981 Apr; 93(8):251-5. PubMed ID: 6266166
[TBL] [Abstract][Full Text] [Related]
28. The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma.
Peled Y; Levavi H; Krissi H; Weill Y; Sabah G; Eitan R
Am J Clin Oncol; 2013 Oct; 36(5):472-4. PubMed ID: 22706176
[TBL] [Abstract][Full Text] [Related]
29. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
[TBL] [Abstract][Full Text] [Related]
30. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer.
Mutch DG; Prat J
Gynecol Oncol; 2014 Jun; 133(3):401-4. PubMed ID: 24878391
[No Abstract] [Full Text] [Related]
31. Better therapeutic trials in ovarian cancer.
Bookman MA; Gilks CB; Kohn EC; Kaplan KO; Huntsman D; Aghajanian C; Birrer MJ; Ledermann JA; Oza AM; Swenerton KD
J Natl Cancer Inst; 2014 Apr; 106(4):dju029. PubMed ID: 24627272
[TBL] [Abstract][Full Text] [Related]
32. Serous papillary adenocarcinomas of the ovary display heterogeneity in their response to chemotherapy.
O'Toole SA; Sheppard BL; McGuinness E; Gleeson NC; Bonnar J
Int J Gynecol Cancer; 2001; 11(5):365-71. PubMed ID: 11737467
[TBL] [Abstract][Full Text] [Related]
33. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
34. Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs.
Moioli M; Barra F; Maramai M; Valenzano Menada M; Vellone VG; Costantini S; Ferrero S
Expert Opin Investig Drugs; 2019 Dec; 28(12):1025-1029. PubMed ID: 31726889
[No Abstract] [Full Text] [Related]
35. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
36. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
[TBL] [Abstract][Full Text] [Related]
37. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
38. Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma.
Kwon HJ; Song SY; Kim HS
Anticancer Res; 2021 Mar; 41(3):1579-1586. PubMed ID: 33788752
[TBL] [Abstract][Full Text] [Related]
39. Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.
Stanley B; Hollis RL; Nunes H; Towler JD; Yan X; Rye T; Dawson C; Mackean MJ; Nussey F; Churchman M; Herrington CS; Gourley C
Gynecol Oncol; 2019 Feb; 152(2):278-285. PubMed ID: 30501904
[TBL] [Abstract][Full Text] [Related]
40. Mucinous ovarian cancer: A therapeutic review.
Xu W; Rush J; Rickett K; Coward JI
Crit Rev Oncol Hematol; 2016 Jun; 102():26-36. PubMed ID: 27083591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
